Nevro to Highlight Body of Clinical Evidence Supporting Expanded Use and Potential New Indications of Company’s Senza Spinal Cord Stimulation Systems Delivering HF10™ Therapy at NANS Annual Meeting

58
0
SHARE

REDWOOD CITY, Calif. and LAS VEGAS, Jan. 12, 2018 — Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of HF10 therapy for patients with chronic pain at the 21st Annual Meeting of the North American Neuromodulation Society (NANS) taking place through January 14 in Las Vegas.

“Our large and growing body of clinical evidence supports the use of HF10 therapy for patients suffering from debilitating chronic pain and looking for alternatives to opioids,” said Rami Elghandour, President and CEO of Nevro. “With a number of studies initiated in a variety of pain areas and indications, we are uniquely positioned to deliver on the promise of neuromodulation by applying our best-in-class therapy to treat a broad array of challenging disease states.  In today's environment, patients and physicians are seeking non-pharmacologic solutions and we are committed to helping patients regain their lives by doing this important work. “

 Key presentations at NANS of studies investigating the safety and effectiveness of HF10 therapy for potential new indications include:

  • SENZA-ULN: a prospective, multicenter clinical trial that evaluated HF10 therapy in subjects with chronic, intractable neck and/or upper limb pain. Patients treated with HF10 therapy experienced significant pain reduction at 12-month follow-up for upper limb and neck pain (an interim VAS pain score less than 2.0 cm for each pain area). The data will be presented by Kasra Amirdelfan, MD.
  • SENZA-PPN: a prospective, multicenter study evaluating HF10 therapy for the treatment of peripheral polyneuropathy, with compelling and consistent interim results at six months that have since prompted the initiation of a large-scale randomized clinical trial for painful diabetic neuropathy (SENZA-PDN). The data will be presented by Sean Li, MD.
  • SENZA-NSRBP: the study design of a randomized, controlled, multicenter trial evaluating HF10 therapy for non-surgical refractory back pain (NSRBP) will be presented. Published feasibility study results have recently demonstrated that patients with non-surgical refractory back pain who received HF10 therapy experienced significant pain reduction (VAS pain score 1.0 cm) at 36 months of follow-up; additionally, these patients reduced opioid usage from 90% at baseline to 12% at 36 months. The presentation will be from Adnan Al-Kaisy, MD.

“The ongoing opioid crisis demands that experts in the field of pain medicine seek therapies that are evidence-based, safe, effective and sustainable for those individuals suffering with chronic pain,” said Dr. B. Todd Sitzman, M.D., M.P.H., Medical Director of Advanced Pain Therapy, PLLC, in Hattiesburg, Mississippi and president-elect, NANS. “The 2018 North American Neuromodulation Society's Annual Meeting showcases high-level data in the field of pain management, including innovative neuromodulation approaches such as HF10 therapy. I look forward to the data presentations, which include research developed at our center regarding potential new indications for HF10 therapy.”

A full list of HF10 therapy-related talks and posters at NANS is available here.

About Chronic Pain

Over 100 million Americans suffer from common chronic pain. It is the primary cause of adult disability in the U.S. and is a costly public health issue. The combined loss of productivity and healthcare costs exceeds $600 billion annually in the U.S. Severe pain can significantly interfere with a person's quality of life and functionality, yet the condition is largely under-treated and misunderstood.

About the Senza System, HF10 Therapy

The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy, an SCS therapy that provides electrical pulses to the spinal cord to alleviate pain. The electrical pulses are delivered by small electrodes on leads that are placed near the spinal cord and are connected to a compact, battery-powered pulse generator implanted under the skin. HF10 therapy is the only SCS therapy indicated to provide pain relief without paresthesia and is also the first SCS therapy to demonstrate superiority to traditional SCS for back and leg pain in a comparative pivotal study. Nevro's innovations in SCS, including the Senza® system and HF10™ therapy, are covered by more than 100 issued U.S. and international patents.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Media Contact:

Nicole Osmer
+1.650.454.0504
[email protected]

Investor Relations Contact:

Katherine Bock
+1.650.433.3247
[email protected]

SOURCE Nevro Corp.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/nevro-to-highlight-body-of-clinical-evidence-supporting-expanded-use-and-potential-new-indications-of-companys-senza-spinal-cord-stimulation-systems-delivering-hf10-therapy-at-nans-annual-meeting-300581889.html

SOURCE Nevro Corp.

Related Links

http://www.nevro.com

Powered by WPeMatico